Interferon alpha-2b gene therapy - Aevi Genomic Medicine

Drug Profile

Interferon alpha-2b gene therapy - Aevi Genomic Medicine

Alternative Names: Infradure; Infradure Biopump

Latest Information Update: 30 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medgenics
  • Class Antivirals; Cytokine genes; IFNA2B gene therapies; Interferons
  • Mechanism of Action Gene transference; IFNA2B expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis D
  • New Molecular Entity No
  • Available For Licensing Yes - Hepatitis B; Hepatitis C; Hepatitis D

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C; Hepatitis D

Most Recent Events

  • 15 Dec 2016 Medgenics is now called Aevi Genomic Medicine
  • 16 Apr 2014 Medgenics withdraws phaseI/II trial in Hepatitis C (recurrent) in Israel prior to enrolment (NCT01430000)
  • 01 Mar 2014 Medgenics terminates phase I/II trial in Hepatitis C in Israel (NCT01433133)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top